-

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Lifecore Biomedical, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Minnesota on behalf of those who acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities during the period of October 7, 2020 to March 19, 2024, inclusive (“the Class Period”). Investors have until September 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[Click here to learn more about the class action]

Between September 2022 and February 2024, Lifecore’s share price declined in response to a series of disclosures concerning material weaknesses in internal control over financial reporting, and delays in making required filings with the U.S. Securities and Exchange Commission (SEC).

The lawsuit alleges that (i) Lifecore maintained deficient internal controls over financial reporting; (ii) as a result, the Company issued several financial statements that were inaccurate and would need to be restated; (iii) Lifecore’s purported remediation efforts with respect to the foregoing deficiencies were ineffective; (iv) all of the foregoing impaired Lifecore’s ability to timely file periodic reports with the SEC in compliance with NASDAQ listing requirements; and (v) accordingly, the Company’s financial position and/or prospects were materially overstated.

If you purchased or otherwise acquired Lifecore securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:LFCR

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

INVESTOR ALERT: Securities Class Action Filed Against Alight, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Alight, Inc. (“Alight” or the “Company”) (NYSE:ALIT) securities during the period of November 12, 2024 through February 18, 2026, inclusive (“the Class Period”). If you suffered a loss on your Alight investments, you have until May 15, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...

INVESTOR ALERT: Securities Class Action Filed Against Grocery Outlet Holding Corp. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Grocery Outlet Holding Corp. (“Grocery Outlet” or the “Company”) (NASDAQ:GO) securities during the period of August 5, 2025 through March 4, 2026, inclusive (“the Class Period”). If you suffered a loss on your Grocery Outlet investments, you have until May 15, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff appl...

FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 27, 2026, Fulgent issued a press release reporting its fourth quarter and full year 20...
Back to Newsroom